Renhong Sun

393 Middle Huaxia Road
Pudong, 201210, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Unique Cysteine-Directed Covalent Inhibition of PRMT1 Suppresses Breast Tumorigenesis.

Unique Cysteine-Directed Covalent Inhibition of PRMT1 Suppresses Breast Tumorigenesis.

Journal: Journal of medicinal chemistry

Published: June 17, 2026

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia.

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia.

Journal: Cancer research

Published: April 02, 2024

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers.

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers.

Journal: Cell chemical biology

Published: October 23, 2023

Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness.

Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness.

Journal: The Journal of biological chemistry

Published: December 08, 2022

Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.

Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.

Journal: European journal of medicinal chemistry

Published: September 25, 2022

Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation.

Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation.

Journal: Chemical communications (Cambridge, England)

Published: August 22, 2022

The PROTAC selectively degrading Bcl-xL represents a novel Hedgehog pathway inhibitor with capacity of combating resistance to Smoothened inhibitors while sparing bone growth.

The PROTAC selectively degrading Bcl-xL represents a novel Hedgehog pathway inhibitor with capacity of combating resistance to Smoothened inhibitors while sparing bone growth.

Journal: Theranostics

Published: May 23, 2022

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs.

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs.

Journal: Nature communications

Published: October 18, 2021

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.

Journal: Journal of medicinal chemistry

Published: June 17, 2021

Construction of an IMiD-based azide library as a kit for PROTAC research.

Construction of an IMiD-based azide library as a kit for PROTAC research.

Journal: Organic & biomolecular chemistry

Published: November 23, 2020

Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.

Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.

Journal: Journal of medicinal chemistry

Published: September 21, 2019

Nickel-Catalyzed [2+2+2] Cycloaddition of Alkyne-Nitriles with Alkynes Assisted by Lewis Acids: Efficient Synthesis of Fused Pyridines.

Nickel-Catalyzed [2+2+2] Cycloaddition of Alkyne-Nitriles with Alkynes Assisted by Lewis Acids: Efficient Synthesis of Fused Pyridines.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: August 11, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026